- Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been
treated with ReFacto® during this study are eligible for participation.
- The patient (or legal guardian) must be willing to give written informed consent
before any study-related procedures are performed.
- A blood sample will be collected from each patient for the purpose of this study and
will be analyzed at one or both of the designated central laboratories.
- Any condition which, in the investigator's opinion, places the patient at undue risk.